A. Preti

754 total citations
17 papers, 602 citations indexed

About

A. Preti is a scholar working on Pathology and Forensic Medicine, Genetics and Oncology. According to data from OpenAlex, A. Preti has authored 17 papers receiving a total of 602 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Pathology and Forensic Medicine, 7 papers in Genetics and 7 papers in Oncology. Recurrent topics in A. Preti's work include Lymphoma Diagnosis and Treatment (9 papers), Chronic Lymphocytic Leukemia Research (7 papers) and CNS Lymphoma Diagnosis and Treatment (4 papers). A. Preti is often cited by papers focused on Lymphoma Diagnosis and Treatment (9 papers), Chronic Lymphocytic Leukemia Research (7 papers) and CNS Lymphoma Diagnosis and Treatment (4 papers). A. Preti collaborates with scholars based in United States and Italy. A. Preti's co-authors include Fernando Cabanillas, Hagop M. Kantarjian, Jorge Romaguera, Elisa Rita Ceresola, Roberto Ferrarese, Filippo Canducci, Maria Alma Rodriguez, Peter McLaughlin, Fredrick B. Hagemeister and A H Sarris and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Clinical Infectious Diseases.

In The Last Decade

A. Preti

17 papers receiving 579 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
A. Preti United States	12	298	222	140	113	107	17	602
Grażyna Wróbel Poland	11	392 1.3×	179 0.8×	40 0.3×	73 0.6×	158 1.5×	29	551
Rosa Ruchlemer Israel	14	297 1.0×	139 0.6×	360 2.6×	50 0.4×	39 0.4×	48	733
Grant McQuaker United Kingdom	11	172 0.6×	187 0.8×	144 1.0×	68 0.6×	47 0.4×	21	548
A. Loverre Italy	6	117 0.4×	474 2.1×	62 0.4×	139 1.2×	30 0.3×	7	906
Tomohiro Kameda Japan	14	121 0.4×	77 0.3×	107 0.8×	41 0.4×	37 0.3×	64	547
Richard Lemal France	11	97 0.3×	139 0.6×	115 0.8×	67 0.6×	26 0.2×	81	512
Orla Tuohy United Kingdom	7	440 1.5×	200 0.9×	42 0.3×	50 0.4×	25 0.2×	8	730
Akie Hirata Japan	8	295 1.0×	313 1.4×	74 0.5×	34 0.3×	22 0.2×	28	513
J. H. Bourhis France	12	59 0.2×	117 0.5×	49 0.3×	148 1.3×	78 0.7×	35	507
Kenneth W. Zamkoff United States	13	130 0.4×	146 0.7×	70 0.5×	45 0.4×	16 0.1×	38	470

Countries citing papers authored by A. Preti

Since Specialization

Citations

This map shows the geographic impact of A. Preti's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by A. Preti with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites A. Preti more than expected).

Fields of papers citing papers by A. Preti

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by A. Preti. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by A. Preti. The network helps show where A. Preti may publish in the future.

Co-authorship network of co-authors of A. Preti

This figure shows the co-authorship network connecting the top 25 collaborators of A. Preti. A scholar is included among the top collaborators of A. Preti based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with A. Preti. A. Preti is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

17 of 17 papers shown

Ceresola, Elisa Rita, Roberto Ferrarese, A. Preti, & Filippo Canducci. (2018). Targeting patients' microbiota with probiotics and natural fibers in adults and children with constipation.. PubMed. 22(20). 7045–7057. 18 indexed citations

Ferrarese, Roberto, Elisa Rita Ceresola, A. Preti, & Filippo Canducci. (2018). Probiotics, prebiotics and synbiotics for weight loss and metabolic syndrome in the microbiome era.. PubMed. 22(21). 7588–7605. 75 indexed citations

Tsimberidou, Apostolia M., Peter McLaughlin, Anas Younes, et al.. (2002). Fludarabine, mitoxantrone, dexamethasone (FND) compared with an alternating triple therapy (ATT) regimen in patients with stage IV indolent lymphoma. Blood. 100(13). 4351–4357. 47 indexed citations

McLaughlin, Paul, Fredrick B. Hagemeister, Maria Alma Rodriguez, et al.. (2000). Safety of fludarabine, mitoxantrone, and dexamethasone combined with rituximab in the treatment of stage IV indolent lymphoma.. PubMed. 27(6 Suppl 12). 37–41. 51 indexed citations

Sarris, A H, K. O. Kliche, A. Preti, et al.. (1999). Interleukin-10 levels are often elevated in serum of adults with Hodgkin's disease and are associated with inferior failure-free survival. Annals of Oncology. 10(4). 433–440. 132 indexed citations

Romaguera, Jorge, Maritza Rodríguez, Peter McLaughlin, et al.. (1999). Phase II Study of Paclitaxel in Combination with Mitoxantrone and Ifosfamide/Mesna for Patients with Relapsed or Refractory Non-Hodgkin's Lymphoma after Failure to Cytarabine/Cisplatin Combination. Investigational New Drugs. 17(2). 187–192. 5 indexed citations

Romaguera, Jorge, Lenore L. Carias, Fredrick B. Hagemeister, et al.. (1998). Use of the International Prognostic Index and the Tumor Score to Detect Poor-Risk Patients with Primary Mediastinal Large B-Cell Lymphoma: A Study of 37 Previously Untreated Patients. Leukemia & lymphoma. 28(3-4). 295–306. 17 indexed citations

Popat, Uday, Richard E. Champlin, William Pugh, et al.. (1998). High-dose chemotherapy for relapsed and refractory diffuse large B-cell lymphoma: mediastinal localization predicts for a favorable outcome.. Journal of Clinical Oncology. 16(1). 63–69. 48 indexed citations

Ayoub, Jean-Pierre, Andreas H. Sarris, F. B. Hagemeister, et al.. (1997). Paclitaxel activity for the treatment of non‐Hodgkin's lymphoma: final report of a phase II trial. British Journal of Haematology. 96(2). 328–332. 31 indexed citations

10.

Younes, Anas, Maria Alma Rodriguez, Peter McLaughlin, et al.. (1997). Phase I Study of Fludarabine and Paclitaxel for the Treatment of Low-Grade Non-Hodgkin's Lymphoma. Leukemia & lymphoma. 26(1-2). 77–82. 11 indexed citations

11.

Younes, Anas, Jean-Pierre Ayoub, A H Sarris, et al.. (1997). Paclitaxel (Taxol®) for the treatment of lymphoma. Annals of Oncology. 8. S129–S131. 5 indexed citations

12.

Younes, Anas, Jean-Pierre Ayoub, A H Sarris, et al.. (1997). Paclitaxel (Taxol) for the treatment of lymphoma.. PubMed. 8 Suppl 1. 129–31. 10 indexed citations

13.

Mera, Junichiro, Estella Whimbey, Linda S. Elting, et al.. (1996). Cytomegalovirus Pneumonia in Adult Nontransplantation Patients with Cancer: Review of 20 Cases Occurring from 1964 Through 1990. Clinical Infectious Diseases. 22(6). 1046–1050. 47 indexed citations

14.

Preti, A., Fredrick B. Hagemeister, Peter McLaughlin, et al.. (1994). Hodgkin's disease with a mediastinal mass greater than 10 cm: Results of four different treatment approaches. Annals of Oncology. 5. S97–S100. 12 indexed citations

15.

Kantarjian, Hagop M., Susan O’Brien, Terry Smith, et al.. (1994). Acute lymphocytic leukaemia in the elderly: characteristics and outsome with the vincristine‐adriamycin‐dexamethasone (VAD) regimen. British Journal of Haematology. 88(1). 94–100. 46 indexed citations

16.

Preti, A. & Hagop M. Kantarjian. (1994). Management of adult acute lymphocytic leukemia: present issues and key challenges.. Journal of Clinical Oncology. 12(6). 1312–1322. 36 indexed citations

17.

Preti, A., Hagop M. Kantarjian, Elihu H. Estey, et al.. (1994). Characteristics and outcome of patients with acute lymphocytic leukemia and myeloperoxidase-positive blasts by electron microscopy.. PubMed. 8(4). 155–67. 11 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact